Laura Villa

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy.

Sorin SpA engages in the research, development, and manufacture of technology products for the treatment of cardiovascular diseases. It operates through the Cardiac Surgery and Cardiac Rhythm business segments. The Cardiac Surgery segment involves in the production and marketing of single-use biomedical devices, systems used to ensure out-of-body circulation in cardiac surgical procedures, and implantable prosthetics to replace or repair heart valves. The Cardiac Rhythm segment deals with the production and marketing of implantable devices and monitoring equipment and accessories to protect against heartbeat disorders. The company was founded in 1956 and is headquartered in Milan, Italy.